Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism

American Journal of Respiratory and Critical Care Medicine

Volumn 168, Issue 4, 2003, Pages 476-480

  Schaaf, Bernhard M ^b   Boehmke, Florian ^b   Esnaashari, Hamed ^b   Seitzer, Ulrike ^b   Kothe, Henning ^b   Maass, Matthias ^b   Zabel, Peter ^b   Dalhoff, Klaus ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b NONE

Author keywords

Genetic predisposition; Lymphotoxin ; Polymorphism; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 10; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALLELE; ARTICLE; BACTERIAL INFECTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; INTERLEUKIN 10 1082 GENE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; STREPTOCOCCUS PNEUMONIAE;

AGED; ALLELES; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; CONFIDENCE INTERVALS; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; INTERLEUKIN-10; LYMPHOTOXIN-ALPHA; MALE; MENINGITIS, PNEUMOCOCCAL; MIDDLE AGED; ODDS RATIO; PNEUMONIA, PNEUMOCOCCAL; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; RISK FACTORS; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0042829185     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200210-1164OC     Document Type: Article

References (49)

1. Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis 2000;4:1066-1078.
2. Georges H, Leroy O, Vandenbussche C, Guery B, Alfandari S, Tronchon L, Beaucaire G. Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med 1999;25:198-206.
3. Rodriguez-Gaspar M, Santolaria F, Jarque-Lopez A, Gonzalez-Reimers E, Milena A, de la Vega MJ, Rodriguez-Rodriguez E, Gomez-Sirvent JL. Prognostic value of cytokines in SIRS general medical patients. Cytokine 2001;15:232-236.
4. Latifi SQ, O'Riordan MA, Levine AD. Interleukin-10 controls the onset of irreversible septic shock. Infect Immun 2002;70:4441-4446.
5. van der Poll T, Marchant A, van Deventer SJ. The role of interleukin-10 in the pathogenesis of bacterial infection. Clin Microbiol Infect 1997; 3:605-607.
6. Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter RM, Standiford TJ. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999;162:392-399.
7. van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996;174:994-1000.
8. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mahieu P, Malaise M, De Groote D, Louis R, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-406.
9. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996;24:381-384.
10. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.
11. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988;318:727-732.
12. Roy S, Knox K, Segal S, Griffiths D, Moore CE, Welsh KI, Smarason A, Day NP, McPheat WL, Crook DW, et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 2002; 359:1569-1573.
13. Friedman G, Jankowski S, Marchant A, Goldman M, Kahn RJ, Vincent JL. Blood interleukin 10 levels parallel the severity of septic shock. J Crit Care 1997;12:183-187.
14. Gomez-Jimenez J, Martin MC, Sauri R, Segura RM, Esteban F, Ruiz JC, Nuvials X, Boveda JL, Peracaula R, Salgado A. Interleukin-10 and the monocyte/macrophage-induced inflammatory response in septic shock. J Infect Dis 1995;171:472-475.
15. Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 1995;171:229-232.
16. Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001; 163:1599-1604.
17. Schaaf B, Böhmke F, Esnaashari H, Rupp J, Maass M, Zabel P, Dalhoff K. IL 10 polymorphism in pneumococcal infection: association with septic shock [abstract]. San Diego: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002;B-953, p. 48.
18. Schaaf B, Esnaashari H, Seitzer U, Zabel P, Maass M, Katus H, Dalhoff K. Does TNF alpha gene polymorphism predispose for severe pneumococcal infection? [abstract] Eur Respir J 2000;16:513s.
19. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-243.
20. Wilson AG, di Giovine FS, Blakemore AIF, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992;1:353.
21. Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMSPCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol 1999;7:127-128.
22. Dalhoff K, Hansen F, Dromann D, Schaaf B, Aries SP, Braun J. Inhibition of neutrophil apoptosis and modulation of the inflammatory response by granulocyte colony-stimulating factor in healthy and ethanol-treated human volunteers. J Infect Dis 1998;178:891-895.
23. Westfall PH, Young SS. Resampling-based multiple testing. New York: John Wiley; 1993.
24. Reynard MP, Turner D, Navarrete CV. Allele frequencies of polymorphisms of the tumour necrosis factor-alpha, interleukin-10, interferon-gamma and interleukin-2 genes in a North European Caucasoid group from the UK. Eur J Immunogenet 2000;27:241-249.
25. Seitzer U, Swider C, Stuber F, Suchnicki K, Lange A, Richter E, Zabel P, Muller-Quernheim J, Flad HD, Gerdes J. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine 1997;9:787-790.
26. Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Hohler T. Differential regulation of interleukin-10 production by genetic and environmental factors: a twin study. Genes Immun 2002;3:407-413.
27. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP, Vandenbrouke JP. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;349:170-173.
28. Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001;166:3915-3922.
29. Miura Y, Thoburn CJ, Bright EC, Chen W, Nakao S, Hess AD. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD. Blood 2002;100:2650-2658.
30. Simpson SQ, Singh R, Bice DE. Heat-killed pneumococci and pneumococcal capsular polysaccharides stimulate tumor necrosis factor-alpha production by murine macrophages. Am J Respir Cell Mol Biol 1994; 10:284-289.
31. Zanotti S, Kumar A, Kumar A. Cytokine modulation in sepsis and septic shock. Expert Opin Investig Drugs 2002;11:1061-1075.
32. Bogdan C, Nathan C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann N Y Acad Sci 1993;685:713-739.
33. Sfeir T, Saha DC, Astiz M, Rackow EC. Role of interleukin-10 in monocyte hyporesponsiveness associated with septic shock. Crit Care Med 2001;29:129-133.
34. Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 2002;166:1475-1482.
35. Glynn P, Coakley R, Kilgallen I, Murphy N, O'Neill S. Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax 1999;54:51-55.
36. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998;351:950-953.
37. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000;181: 176-180.
38. Marchant A, Deviere J, Byl B, De Groote D, Vincent JL, Goldman M. Interleukin-10 production during septicaemia. Lancet 1994;343:707-708.
39. van der Pol WL, Huizinga TW, Vidarsson G, van der Linden MW, Jansen MD, Keijsers V, de Straat FG, Westerdaal NA, de Winkel JG, Westendorp RG. Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001;184:1548-1555.
40. Girndt M, Kaul H, Sester U, Ulrich C, Sester M, Georg T, Kohler H. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 2002;62:949-955.
41. Lopez-Maderuelo D, Arnalich F, Serantes R, Gonzalez A, Codoceo R, Madero R, Vazquez JJ, Montiel C. Interferon gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis. Am J Respir Crit Care Med 2003;167:970-975.
42. Appoloni O, Dupont E, Vandercruys M, Andriens M, Duchateau J, Vincent JL. Association of tumor necrosis factor-2 allele with plasma tumor necrosis factor-alpha levels and mortality from septic shock. Am J Med 2001;110:486-488.
43. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riche F, et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999;282:561-568.
44. Tang GJ, Huang SL, Yien HW, Chen WS, Chi CW, Wu CW, Lui WY, Chiu JH, Lee TY. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 2000;28:2733-2736.
45. Kalechman Y, Gafter U, Gal R, Rushkin G, Yan D, Albeck M, Sredni B. Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention. J Immunol 2002;169:384-392.
46. van der Poll T, Keogh CV, Buurman WA, Lowry SF. Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med 1997; 155:603-608.
47. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein: the Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697-1702.
48. Remick DG, Garg SJ, Newcomb DE, Wollenberg G, Huie TK, Bolgos GL. Exogenous interleukin-10 fails to decrease the mortality or morbidity of sepsis. Crit Care Med 1998;26:895-904.
49. Wang E, Simard M, Ouellet N, Bergeron Y, Beauchamp D, Bergeron MG. Modulation of cytokines and chemokines, limited pulmonary vascular bed permeability, and prevention of septicemia and death with ceftriaxone and interleukin-10 in pneumococcal pneumonia. J Infect Dis 2000;182:1255-1259.